RELVAR

This brand name is authorized in Austria, Brazil, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, South Africa

Active ingredients

The drug RELVAR contains a combination of these active pharmaceutical ingredients (APIs):

1	Fluticasone furoate UNII JS86977WNV - FLUTICASONE FUROATE
	Fluticasone furoate is a synthetic trifluorinated corticosteroid that possesses a very high affinity for the glucocorticoid receptor and has a potent anti-inflammatory action.
	Read more about Fluticasone furoate
2	Vilanterol UNII 40AHO2C6DG - VILANTEROL TRIFENATATE
	Vilanterol is a selective long-acting, beta2-adrenergic agonist (LABA). The pharmacologic effects of beta2-adrenoceptor agonist active substances, including vilanterol, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
	Read more about Vilanterol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RELVAR ELLIPTA Inhalation powder, pre-dispensed	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03AK10	Vilanterol and fluticasone furoate	R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AK Adrenergics and other drugs for obstructive airway diseases
Discover more medicines within R03AK10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	510614060051902, 510614060052002, 510614060052102, 510614060052202
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	02359975, 02359981, 02360725, 02360754, 16897127, 16897133, 17522375, 17522381, 17824509, 17824515
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	298-MEE-0514, 380-MEE-0714
EE	Ravimiamet	1632327, 1632338, 1632349, 1632350, 1632361, 1632372
ES	Centro de información online de medicamentos de la AEMPS	113886002, 113886005
FI	Lääkealan turvallisuus- ja kehittämiskeskus	125317, 386095, 413225, 495151
FR	Base de données publique des médicaments	61740809, 64122611
GB	Medicines & Healthcare Products Regulatory Agency	236218, 236221, 375330, 375334, 379941, 379943, 381654, 381656
HK	Department of Health Drug Office	62693, 62694
IE	Health Products Regulatory Authority	19732, 19733, 19734, 19758
IL	מִשְׂרַד הַבְּרִיאוּת	7409, 7410
IT	Agenzia del Farmaco	043154018, 043154020, 043154032, 043154044, 043154057, 043154069
JP	医薬品医療機器総合機構	2290803G1028, 2290803G2024, 2290803G3020, 2290803G4027
LT	Valstybinė vaistų kontrolės tarnyba	1072104, 1072105, 1072106, 1072107, 1072108, 1072109
NL	Z-Index G-Standaard, PRK	125334, 125342
NZ	Medicines and Medical Devices Safety Authority	15585, 15586
PL	Rejestru Produktów Leczniczych	100304330, 100304346
SG	Health Sciences Authority	14736P, 14737P
TN	Direction de la Pharmacie et du Médicament	2883051, 2883052
TR	İlaç ve Tıbbi Cihaz Kurumu	8699522559923, 8699522559930, 8699522559947, 8699522559954, 8699522559961, 8699522559978
ZA	Health Products Regulatory Authority	48/21.5.1/0250, 48/21.5.1/249